nCOVID-19 Pandemic: From Molecular Pathogenesis to Potential Investigational Therapeutics

Md Tanvir Kabir, Md Sahab Uddin, Md Farhad Hossain, Jawaher A. Abdulhakim, Md Asraful Alam, Ghulam Md Ashraf, Simona G. Bungau, May N. Bin-Jumah, Mohamed M. Abdel-Daim, Lotfi Aleya

Risultato della ricerca: Articlepeer review

16 Citazioni (Scopus)

Abstract

In December 2019, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related epidemic was first observed in Wuhan, China. In 2020, owing to the highly infectious and deadly nature of the virus, this widespread novel coronavirus disease 2019 (nCOVID-19) became a worldwide pandemic. Studies have revealed that various environmental factors including temperature, humidity, and air pollution may also affect the transmission pattern of COVID-19. Unfortunately, still, there is no specific drug that has been validated in large-scale studies to treat patients with confirmed nCOVID-19. However, remdesivir, an inhibitor of RNA-dependent RNA polymerase (RdRp), has appeared as an auspicious antiviral drug. Currently, a large-scale study on remdesivir (i.e., 200 mg on first day, then 100 mg once/day) is ongoing to evaluate its clinical efficacy to treat nCOVID-19. Good antiviral activity against SARS-CoV-2 was not observed with the use of lopinavir/ritonavir (LPV/r). Nonetheless, the combination of umifenovir and LPV/r was found to have better antiviral activity. Furthermore, a combination of hydroxychloroquine (i.e., 200 mg 3 times/day) and azithromycin (i.e., 500 mg on first day, then 250 mg/day from day 2–5) also exhibited good activity. Currently, there are also ongoing studies to evaluate the efficacy of teicoplanin and monoclonal and polyclonal antibodies against SARS-CoV-2. Thus, in this article, we have analyzed the genetic diversity and molecular pathogenesis of nCOVID-19. We also present possible therapeutic options for nCOVID-19 patients.
Lingua originaleEnglish
RivistaFrontiers in Cell and Developmental Biology
Volume8
DOI
Stato di pubblicazionePublished - 10 lug 2020

Fingerprint Entra nei temi di ricerca di 'nCOVID-19 Pandemic: From Molecular Pathogenesis to Potential Investigational Therapeutics'. Insieme formano una fingerprint unica.

Cita questo